Neuregulin promotes autophagic cell death of prostate cancer cells

Prostate

Volumn 55, Issue 2, 2003, Pages 147-157

  Tal Or, Pazit ^a   Di Segni, Ayelet ^a   Lupowitz, Zipora ^a   Pinkas Kramarski, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epidermal growth factor; ErbB HER family; Neu differentiation factor; Signal transduction; Tyrosine kinase

Indexed keywords

3 METHYLADENINE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; NEU DIFFERENTIATION FACTOR;

ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MALE; ONCOGENE NEU; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADENINE; AMINO ACID CHLOROMETHYL KETONES; AUTOPHAGY; CELL DEATH; CELL DIVISION; CHROMONES; CYSTEINE PROTEINASE INHIBITORS; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; LIGANDS; MALE; MORPHOLINES; NEUREGULINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0037404978     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10200     Document Type: Article

References (53)

1. Harris AL, Nicholson S, Sainsbury R, Wright C, Farndon J. Epidermal growth factor receptor and other oncogenes as prognostic markers. J Natl Cancer Inst Monogr 1992;11:181-187.
2. Stancovski I, Sela M, Yarden Y. Molecular and clinical aspects of the Neu/ErbB-2 receptor tyrosine kinase. In: Lippman M, Dikson R, editors. Regulatory mechanisms of breast cancer. Boston: Kulwer Academic Publishers; 1994. p 161-191.
3. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia 1997;2:97-107.
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
5. Peles E, Yarden Y. Neu and its ligands: From an oncogene to neural factors. BioEssays 1993;15:815-824.
6. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-223.
7. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeburg PH. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-425.
8. Coussens L, Yang Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
9. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-230.
10. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986;319:230-234.
11. Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VI, Todaro GJ, Shoyab M. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci USA 1990;87:4905-4909.
12. Plowman DG, Culouscou J-M, Withney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M. Ligand-specific activation of HER-4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993;90:1746-1750.
13. Kraus MH, Issing M, Popescu NC, Aaronson SA. Isolation and characterization of ErbB-3, a third member of the ErbB/epidermal growth factor receptor family: Evidence for over-expression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86:9193-9197.
14. Wen D, Peles E, Cupples R, Suggs SV, Bacus SS, Luo Y, Trail G, Hu S, Silbiger SM, Ben-Levy R, Luo Y, Yarden Y. Neu Differentiation Factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 1992;69:559-572.
15. Pinkas-Kramarski R, Yarden Y. Neu differentiation factors. In: Aggarwal BB, Gutterman JU, editors. An entry to human cytokines: Handbook for basic and clinical research, Vol II. Cambridge, MA: Blackwell Scientific Publications, Inc.; 1995. p 340-360.
16. Corfas G, Fall DL, Fischbach GD. Aria, a protein that stimulates acetylcholine receptor synthesis, also induces tyrosine phosphorylation of a 185-kDa muscle transmembrane protein. Proc Natl Acad Sci USA 1993;90:1624-1628.
17. Marchionni MA, Goodearl ADJ, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Denehy F, Misumi D, Sudhalter J, Kobayashi K, Wroblewski D, Lynch C, Baldassare M, Hiles I, Davis JB, Hsuan JJ, Totty NF, Otsu M, McBury RN, Waterfield MD, Stroobant P, Gwynne D. Glial growth factors are alternatively spliced erbB-2 ligands expressed in the nervous system. Nature 1993;362:312-318.
18. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
19. Pinkas-Kramarski R, Shelly M, Ratzkin JB, Yarden Y. NDF/neuregulin isoforms induce distinct receptor heterodimers. J Biol Chem 1996;271:19029-19032.
20. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin JB, Sela M, Yarden Y. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467.
21. Riese DJ, van Raaij TM, Plowman GD, Andrews GC, Stern DF. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 1995;15:5770-5776.
22. Hung MC, Zhang X, Yan DH, Zhang HZ, He GP, Zhang TQ, Shi DR. Aberrant expression of the c-erbB-2/neu proto-oncogene in ovarian cancer. Cancer Lett 1992;61:95-103.
23. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RCJ. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
24. Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990;50:5184-5187.
25. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. Br J Urol 1994;74:214-220.
26. Kuhn EJ, Kurnot RA, Sesterhenn IA, Chang EH, Moul JW. Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. J Urol 1993;150:1427-1433.
27. Myers RB, Srivastava S, Oelschlager DK, Grizzle WE. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 1994;86:1140-1145.
28. Latil A, Baron JC, Cussenot O, Fournier G, Boccon-Gibod L, Le Duc A, Lidereau R. Oncogene amplifications in early-stage human prostate carcinomas. Int J Cancer 1994;59:637-638.
29. Zhau HE, Wan DS, Zhou J, Miller GJ, von Eschenbach AC. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol Carcinog 1992;5:320-327.
30. Sikes RA, Chung LW. Acquisition of a tumorigenic pheno type by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene. Cancer Res 1992;52:3174-3181.
31. Schwartz SJ, Caceres C, Morote J, De Torres I, Rodriguez-Vallejo JM, Gonzalez J, Reventos J. Gains of the relative genomic content of erbB-1 and erbB-2 in prostate carcinoma and their association with metastasis. Int J Oncol 1999;14:367-371.
32. Limonta P, Dondi D, Marelli MM, Moretti RM, Negri-Cesi P, Motta M. Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors. J Steroid Biochem Mol Biol 1995;53:401-405.
33. Cohen DW, Simak R, Fair WR, Melamed J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues. J Urol 1994;152:2120-2124.
34. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545-550.
35. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 1992;1992:5887-5892.
36. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996;19:419-427.
37. Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997;3:21-30.
38. Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Ben-Levy R, Yarden Y. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 1992;69:205-216.
39. Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Cancer Res 1997;57:3804-3811.
40. Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, Hynes NE. NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: Role of PI3 kinase and p38 MAP kinase pathways. Oncogene 1999;18:3440-3451.
41. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997;15:2705-2716.
42. Mosman T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
43. Seglen PO, Gordon PB. 3-Methyladenine: Specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci USA 1982;79:1889-1892.
44. Seglen PO, Bohley P. Autophagy and other vacuolar protein degradation mechanisms. Experientia 1992;48:158-172.
45. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochem Biophys Acta 1994;1198:165-184.
46. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
47. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987;1:423-430.
48. Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, Kabbinavar FF, Pietras RJ, Pisacane P, Sliwkowski MX, Slamon DJ. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 1999;18:6050-6062.
49. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick C, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996;12:2535-2547.
50. Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KLI. Coexpression of erbB2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 1994;269:14661-14665.
51. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897.
52. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 1997;243:240-246.
53. Petiot A, Ogier-Denis E, Blommaart EF, Meijer AJ, Codogno P. Distinct classes of phosphatidylinositol 3′-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells. J Biol Chem 2000;275:992-998.